Skip to content

Study · Animal study (in vivo) · mouse · 2014

6 results

The protective effects of the melanocortin receptor (MCR) agonist, melanotan-II (MTII), against binge-like ethanol drinking are facilitated by deletion of the MC3 receptor in mice.

Olney JJ, Sprow GM, Navarro M, Thiele TE

Neuropeptides15 Nov 2013Cited by 16 (Europe PMC)

PMID24290566 (opens in a new tab)PMCIDPMC3946855 (opens in a new tab)DOI10.1016/j.npep.2013.11.001 (opens in a new tab)PepBankPUB-24290566
Source linkPubMedAsk about this study
Jump to 6 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study6

6 results from studies that gave the peptide. No result from this study comes from people.

  1. 01AnimalAnimal study (in vivo)Efficacy outcome

    In wild-type MC3R+/+ mice, central MTII blunted binge-like ethanol drinking.

    In plain wordsIn normal mice, MTII given into the brain reduced binge-like alcohol drinking.

    Peptide
    Melanotan II
    Outcome
    DecreaseBinge-like ethanol drinking in MC3R+/+ mice
    Study

    mousen: not reported in source

    wild-type MC3R+/+ and MC3R-/- mice, drinking-in-the-dark binge model
    Outcome group
    Addiction, withdrawal and alcohol intake · Mental health and mood
    Studied dose
    0.25, 0.50 or 1.0 µg · intracerebroventricularAs given in this study (mouse).

    Source sentences

    Summary
    Consistent with previous findings, central administration of MTII blunted binge-like ethanol drinking in both MC3R+/+ and MC3R-/- mice.
    1 context sentence
    Summary · context
    Wild-type MC3R+/+ and MC3R-/- mice were given intracerebroventricular (i.c.v.) infusion of MTII (0.0, 0.25, 0.50, or 1.0 μg) prior to the onset of a 4-h testing period in which mice were given access to 20% (v/v) ethanol.
  2. 02AnimalAnimal study (in vivo)Efficacy outcome

    In MC3R-/- mice, central MTII blunted binge-like ethanol drinking.

    In plain wordsIn mice lacking the MC3 receptor, MTII given into the brain reduced binge-like alcohol drinking.

    Peptide
    Melanotan II
    Outcome
    DecreaseBinge-like ethanol drinking in MC3R-/- mice
    Study

    mousen: not reported in source

    wild-type MC3R+/+ and MC3R-/- mice, drinking-in-the-dark binge model
    Outcome group
    Addiction, withdrawal and alcohol intake · Mental health and mood
    Studied dose
    0.25, 0.50 or 1.0 µg · intracerebroventricularAs given in this study (mouse).

    Source sentences

    Summary
    Consistent with previous findings, central administration of MTII blunted binge-like ethanol drinking in both MC3R+/+ and MC3R-/- mice.
    1 context sentence
    Summary · context
    Wild-type MC3R+/+ and MC3R-/- mice were given intracerebroventricular (i.c.v.) infusion of MTII (0.0, 0.25, 0.50, or 1.0 μg) prior to the onset of a 4-h testing period in which mice were given access to 20% (v/v) ethanol.
  3. 03AnimalAnimal study (in vivo)Efficacy outcome

    In MC3R-/- mice, all MTII doses blunted binge-like ethanol drinking during the first hour of testing.

    In plain wordsIn mice lacking the MC3 receptor, every MTII dose reduced alcohol drinking in the first hour.

    Peptide
    Melanotan II
    Outcome
    DecreaseFirst-hour binge-like drinking in MC3R-/- mice
    Study

    mousen: not reported in source

    wild-type MC3R+/+ and MC3R-/- mice, drinking-in-the-dark binge model
    Outcome group
    Addiction, withdrawal and alcohol intake · Mental health and mood
    Studied dose
    0.25, 0.50 and 1.0 µg · intracerebroventricularAs given in this study (mouse).

    Source sentences

    Summary
    all doses of MTII blunted binge-like ethanol drinking in MC3R-/- mice during the first hour of testing
    1 context sentence
    Summary · context
    Wild-type MC3R+/+ and MC3R-/- mice were given intracerebroventricular (i.c.v.) infusion of MTII (0.0, 0.25, 0.50, or 1.0 μg) prior to the onset of a 4-h testing period in which mice were given access to 20% (v/v) ethanol.
  4. 04AnimalAnimal study (in vivo)Efficacy outcome

    In wild-type MC3R+/+ mice, only the 1.0 µg MTII dose reduced binge-like drinking in the first hour.

    In plain wordsIn normal mice, only the highest MTII dose reduced alcohol drinking in the first hour.

    Peptide
    Melanotan II
    Outcome
    DecreaseFirst-hour binge-like drinking in MC3R+/+ mice at 1.0 µg
    Study

    mousen: not reported in source

    wild-type MC3R+/+ and MC3R-/- mice, drinking-in-the-dark binge model
    Outcome group
    Addiction, withdrawal and alcohol intake · Mental health and mood
    Studied dose
    1.0 µg · intracerebroventricularAs given in this study (mouse).

    Source sentences

    Summary
    only the 1.0 μg dose reduced binge-like drinking in MC3R+/+ mice
    1 context sentence
    Summary · context
    Wild-type MC3R+/+ and MC3R-/- mice were given intracerebroventricular (i.c.v.) infusion of MTII (0.0, 0.25, 0.50, or 1.0 μg) prior to the onset of a 4-h testing period in which mice were given access to 20% (v/v) ethanol.
  5. 05AnimalAnimal study (in vivo)Efficacy outcome

    In wild-type MC3R+/+ mice, the lower MTII doses (0.25 and 0.50 µg) did not reduce first-hour binge-like drinking, as only the 1.0 µg dose did.

    In plain wordsIn normal mice, the two lower MTII doses did not reduce alcohol drinking in the first hour.

    Peptide
    Melanotan II
    Outcome
    No significant changeFirst-hour binge-like drinking in MC3R+/+ mice at lower doses
    Study

    mousen: not reported in source

    wild-type MC3R+/+ and MC3R-/- mice, drinking-in-the-dark binge model
    Outcome group
    Addiction, withdrawal and alcohol intake · Mental health and mood
    Studied dose
    0.25 and 0.50 µg · intracerebroventricularAs given in this study (mouse).

    Source sentences

    Summary
    only the 1.0 μg dose reduced binge-like drinking in MC3R+/+ mice
    1 context sentence
    Summary · context
    Wild-type MC3R+/+ and MC3R-/- mice were given intracerebroventricular (i.c.v.) infusion of MTII (0.0, 0.25, 0.50, or 1.0 μg) prior to the onset of a 4-h testing period in which mice were given access to 20% (v/v) ethanol.
  6. 06AnimalAnimal study (in vivo)Efficacy outcome

    MC3R-/- mice were more sensitive than MC3R+/+ mice to the protective effects of MTII against binge-like ethanol drinking.

    In plain wordsMice lacking the MC3 receptor responded more strongly to MTII's reduction of alcohol drinking than normal mice.

    Peptide
    Melanotan II
    Outcome
    DecreaseSensitivity to MTII, MC3R-/- versus MC3R+/+ mice
    Study

    mousen: not reported in source

    wild-type MC3R+/+ and MC3R-/- mice, drinking-in-the-dark binge model
    Comparator
    MC3R+/+ mice
    Outcome group
    Addiction, withdrawal and alcohol intake · Mental health and mood
    Studied dose
    Dose not stated · intracerebroventricularAs given in this study (mouse).

    Source sentences

    Summary
    Thus, MC3R-/- mice were more sensitive to the protective effects of MTII.
    1 context sentence
    Summary · context
    Wild-type MC3R+/+ and MC3R-/- mice were given intracerebroventricular (i.c.v.) infusion of MTII (0.0, 0.25, 0.50, or 1.0 μg) prior to the onset of a 4-h testing period in which mice were given access to 20% (v/v) ethanol.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    9 Oct 2026, 18:17 UTC

    Study results updated

  2. Version 1

    9 Oct 2026, 03:04 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.